ClearPoint Neuro announces the appointment of Mazin Sabra as

SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) — ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy platform company enabling navigation and delivery to the brain, today today announced that Mazin Sabra will join the Company effective October 10e as Chief Operating Officer. Mr. Sabra will report directly to Joe Burnett, CEO of ClearPoint Neuro, and will be part of the company’s management team.

“We are thrilled to have Mazin join our team and bring his valuable and relevant skills to our organization,” commented Joe Burnett, President and CEO of ClearPoint Neuro. “Our pharmaceutical and device partners view ClearPoint in many ways as a critical supplier and part of their supply chain. They cannot get their drug or therapy to target unless we perform at the highest level. Mazin’s experience in quality, procurement and supply chain in huge organizations like Philips and Stryker should give our partners increased confidence that we continue to invest in skill sets. they need to create industry-leading products that are predictably delivered and available globally.

Mr. Sabra has served as Vice President of Supplier Quality Engineering for Philips since April 2021. In this role, he led a global team responsible for supplier quality performance for a range of Philips’ portfolio, from medical devices class III to consumer products. Prior to this role, he held several positions at Philips since June 2016, including as Vice President of Supply Engineering for Philips Connected Care business, as well as Senior Director of Supply Engineering. procurement for its image-guided therapy devices business. In these roles, Mr. Sabra was responsible for setting the company’s sourcing strategy, sourcing risk management, design for excellence for product development, profitability and growth.

Prior to joining Philips, Mr. Sabra spent 11 years at Stryker Corporation, holding several management positions. From 2011 to 2016, he was Director of Strategic Sourcing in Asia for Stryker, based in Suzhou, China. In this role, he was responsible for all Asia-based suppliers supplying products to more than 14 Stryker manufacturing sites around the world, including all supplier activities for three Chinese manufacturing plants and Stryker’s global technology center in India. Mr. Sabra holds a bachelor’s degree in industrial and systems engineering from the University of Michigan.

“I am very excited to be part of ClearPoint Neuro’s growth journey,” said Mazin Sabra. “I look forward to partnering with the leadership team to create a platform for sustainable growth with new product introductions and a scalable operational infrastructure.”

About ClearPoint Neuro

ClearPoint Neuro’s mission is to improve and restore the quality of life for patients and their families by enabling therapies for the most complex neurological disorders with pinpoint precision. Applications of the company’s current product portfolio include deep brain stimulation, laser ablation, biopsy, neuroaspiration, and delivery of drugs, biologics, and gene therapy to the brain. The clear point® The Neuro Navigation System is FDA cleared, CE marked, and installed at over 60 active sites in the United States, Canada, and Europe. ClearPoint Neuro partners with more than 45 pharmaceutical and biotechnology companies, academic institutions, and contract research organizations providing solutions for direct CNS delivery of therapeutics in preclinical studies and clinical trials in the whole world. To date, more than 5,000 cases have been treated and supported by the company’s team of field clinical specialists, who provide support and services to our customers and partners worldwide. For more information, visit

Forward-looking statements

Statements in this press release regarding the Company’s plans, growth and strategies may include forward-looking statements within the context of federal securities laws. Statements regarding future events, developments and future performance of the Company, as well as management’s expectations, beliefs, plans, estimates or projections regarding the future, are forward-looking statements within the meaning of such laws. Uncertainties and risks may cause the Company’s actual results to differ materially from those expressed or implied by the forward-looking statements. Particular risks and uncertainties include those related to: the impact of the COVID-19 pandemic and global instability, supply chain disruptions, labor shortages and inflationary conditions; future revenues from sales of the Company’s ClearPoint Neuro navigation system and other new products offered by the Company; the Company’s ability to commercialize, commercialize and achieve broader market acceptance for the Company’s ClearPoint Neuro navigation system and other new products offered by the Company; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of our products and services in the delivery of therapies; and the risks inherent in the research and development of new products. More detailed information about these and other factors that could affect the Company’s actual results is described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended 31 December 2021, and in the Company’s Quarterly Report on Form 10-Q for the three months ended June 30, 2022, both of which have been filed with the Securities and Exchange Commission.

A photo accompanying this announcement is available at

Back To Top